The tweet was deleted by the author.
But we saved everything 🙂.
Humacyte has released a press statement detailing their presentations scheduled at the VEITH symposium.
The company highlights today's sessions, including the Podium Session 8 on Concourse A at 11:05 am EST, focusing on the clinical effectiveness of advanced solutions.
The company's ongoing engagement at the VEITH Symposium builds upon its continued emphasis on innovation, as previously seen with the introduction of its bioengineered vessel, Symvess. These developments further underscore Humacyte's commitment to advancing education on its Acellular Tissue Engineered Vessel technology, setting the stage for new benchmarks in vascular therapy and clinical outcomes.